Latest Insider Positions


Kaula Norbert is listed as an insider in the following companies: NVTR / Nuvectra Corporation Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Holdings

Security Title Post Shares
NVTR / Nuvectra EVP, Research & Development 15,467

Latest Transactions

Latest
Tran Date
Security Code Shares Post Shares Percent
Change
Share
Price
Tran
Value
Post
Value
Percent
Change
2018-08-12 NVTR / Nuvectra M 2,141 15,467 16.07 18.14 38,838
2018-07-07 NVTR / Nuvectra M 499 13,326 3.89 18.09 9,027
2018-05-12 NVTR / Nuvectra M 8,559 12,827 200.54 16.73 143,192
2018-04-07 NVTR / Nuvectra M 499 4,268 13.24 13.05 6,512
2018-01-07 NVTR / Nuvectra M 499 3,769 15.26 7.86 3,922
2017-10-07 NVTR / Nuvectra M 499 3,270 18.01 13.44 6,707
2017-07-07 NVTR / Nuvectra M 499 2,771 21.96 13 6,487
2017-04-07 NVTR / Nuvectra M 1,995 2,272 720.22 6.36 12,688
2016-12-30 NVTR / Nuvectra M 277 277 5.03 1,393
2016-04-08 NVTR / Nuvectra A 5,985 5,985
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)

Peers of Kaula Norbert include the following: BERGER WALTER Z, Bihl Anthony P III, DREES SCOTT F, Fahey Kathy Jo, GREATBATCH, INC., HAWARI KENNETH G, Hanchin Joseph Paul, Hickman Thomas Kelley, JOHNSON DAVID D, Kosharek Jennifer, MILLER JOSEPH A, PARKS FRED B, Tranchina Benjamin, Tremmel Jon T, Zelibor Thomas Edward, . Peers are determined by cross-linking the filings of Kaula Norbert with insider filings of others at the same companies.

Related News Stories

Implied Volatility Surging for Nuvectra (NVTR) Stock Options

2018-09-24 zacks
Investors in Nuvectra Corporation (NVTR - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the Nov 16, 2018 $20.00 Call had some of the highest implied volatility of all equity options today.

Are Options Traders Betting on a Big Move in Nuvectra (NVTR) Stock?

2018-08-21 zacks
Investors in Nuvectra Corporation (NVTR - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the Sep 21, 2018 $17.50 Put had some of the highest implied volatility of all equity options today. What is Implied Volatility? Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other.

Nuvectra Corporation (NVTR) CEO Scott Drees on Q2 2018 Results - Earnings Call Transcript

2018-08-12 seekingalpha
Good day, ladies and gentlemen, and welcome to the Q2 2018 Nuvectra Earnings Conference Call. [Operator Instructions] As a reminder, this conference call may be recorded. (3-0)

Your Daily Pharma Scoop: Redhill's New Patent, Nuvectra Slips, Teligent Gains

2018-07-03 seekingalpha
RedHill Biopharma (RDHL) announced that two new patents covering Crohn's disease candidate RHB-104 are notified by USPTO and the European Patent Office. The candidate is currently in Phase 3 development. The patents will be in effect until 2029. The company has an important upcoming catalyst related to its RHB-104 candidate. Topline Phase 3 data of RHB-104 trial MAP-US on Crohn's disease expected in early August 2018. (27-2)

Why Nuvectra Is Monday’s Big Biotech Loser

2018-07-02 247wallst
Nuvectra Corp. (NASDAQ: NVTR) shares were crushed on Monday after the company announced an update on its U.S. Food and Drug Administration (FDA) premarket approval (PMA) application and its TÜV SÜD application for CE Mark in Europe for Virtis. (1-0)